前列腺癌穿刺活检组织中端粒酶活性检测及意义

目的;探讨前列腺穿刺活检标本中端粒酶（TE）活性检测在前列腺癌（PCA）诊断、鉴别诊断及评估PCA生物学行为中的意义。方法：应用端粒重复片段扩增法（TRAP法）检测疑为前列腺癌患者的前列腺穿刺活检标本的TE活性,并比较TE活性水平与PCA病理分化程度及转移情况的关系。结果：PCA组织中TE活性明显高于前列腺增生（BPH）组织。PCA组织中TE活性水平与其病理分化程度及转移情况相关。结论：PCA患者的前列有朱穿刺活检组织中的TE活性显著高于BPH者,且与其病理分化程度及转移情况相关。提示TE可能成为PCA早期诊断及鉴别诊断的一项新的分子瘤标,并可能与PCA的生物学行为相关。     

输卵管妊娠术后生殖状况及其影响因素分析

目的分析引起输卵管妊娠手术治疗后不同生殖状况的相关因素,探讨改善生殖状况,提高宫内妊娠率的方法.方法对自1999-01-2003-12在中山大学附属第一医院等两家医院的424例输卵管妊娠患者经腹腔镜或剖腹手术治疗后患者生殖状况及其相关影响因素进行多重Logistic回归分析及x2分析,找出引起术后不孕及重复性异位妊娠的原因.结果424例患者术后宫内妊娠177例,占41.7%;出现重复性异位妊娠102例,占24.1%;有145例患者术后仍然未孕,占34.2%.多重Logistic回归分析提示,盆腔炎、不孕、异位妊娠、输卵管手术、输卵管粘连、输卵管伞端闭锁是输卵管妊娠术后不孕及重复性异位妊娠的危险因素.结论积极预防盆腔病变,治疗不孕症是改善输卵管妊娠术后生殖状况的重要手段.     

TCR-T细胞免疫疗法治疗肝细胞癌的研究现状及策略

肝细胞癌是原发性肝癌的主要病理类型,目前的临床治疗方法难以达到理想的效果,迫切需要探索新的、有效的治疗方法。T细胞受体基因工程改造T细胞(TCR-T)疗法因在实体瘤中的成功应用,被认为是最有前景的免疫治疗方式之一。本文主要从TCR-T治疗在肝细胞癌中的研究进展进行综述,并针对性提出一些解决策略,包括优化TCR亲和力、降低毒性反应、减少外源性和内源性TCR双链错配、改善肿瘤微环境、促进TCR-T细胞扩增。     

Thromboprophylaxis in the oldest old with atrial fibrillation: Between Scylla and Charybdis

Within a few decades half of the patients with non-valvular atrial fibrillation (AF) will be older than 80 years. These patients are at particularly high risk of thromboembolism (Scylla) but also of the hemorrhagic complications of thromboprophylaxis (Charybdis). A frequent compromise is to use as antithrombotic agents instead of vitamin-K antagonists aspirin or other antiplatelet drugs, which are ineffective for thromboprophylaxis in the oldest old and definitely not free from a high risk of severe bleeding. All the new direct anticoagulants currently licensed (dabigatran, rivaroxaban, apixaban) are at least as effective as warfarin for thromboprophylaxis in AF, but the risk of the intracranial bleeding, the most feared complication of anticoagulant therapy, is at least halved. In the oldest patients of 80 years of age or more preliminary data, available so far only for dabigatran, indicate that the favorable outcomes of direct anticoagulants are also present in this subgroup, often left untreated for fear of intracranial bleeding. The choice between the different direct anticoagulants is driven by the presence or not of renal insufficiency, the presence and degree of multimorbidity and polypharmacy and by the likelihood or not of poor treatment adherence in patients who are often frail and with some degree of cognitive impairment.